{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:41:46Z","timestamp":1790401306129,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.yebeh.2026.110970","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:40:24Z","timestamp":1773668424000},"page":"110970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Novel epilepsy treatments in clinical development"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-7365","authenticated-orcid":false,"given":"Boulenouar","family":"Mesraoua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1329","authenticated-orcid":false,"given":"Bassel","family":"Abou-Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-7601","authenticated-orcid":false,"given":"Ali A.","family":"Asadi-Pooya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-1227","authenticated-orcid":false,"given":"Hassan Al","family":"Hail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-9266","authenticated-orcid":false,"given":"Majd A","family":"AbuAlrob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2026.110970_b0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2026.110970_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110970_b0015","first-page":"17","article-title":"Drug-resistant epilepsy and surgery","volume":"16","author":"Sheng","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.yebeh.2026.110970_b0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","article-title":"Drug resistance in epilepsy","volume":"22","author":"Perucca","year":"2023","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.yebeh.2026.110970_b0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/a-2580-1187","article-title":"The epilepsy drug pipeline: Update on near-to-market therapies","volume":"45","author":"Elder","year":"2025","journal-title":"Semin Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0030","doi-asserted-by":"crossref","unstructured":"Perucca P, Perucca E. Novel pharmacological therapies in development. Curr Opin Neurol Curr 2026 Jan 30. doi: 10.1097\/WCO.0000000000001456. Online ahead of print.","DOI":"10.1097\/WCO.0000000000001456"},{"issue":"4","key":"10.1016\/j.yebeh.2026.110970_b0035","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/epi.17884","article-title":"Current state of the epilepsy drug and device pipeline","volume":"65","author":"Terman","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","article-title":"New epilepsy therapies in development","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2026.110970_b0045","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 2020;61:2340\u201364. DOI: 10.1111\/epi.16725.","DOI":"10.1111\/epi.16725"},{"key":"10.1016\/j.yebeh.2026.110970_b0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40263-024-01155-3","article-title":"Targeting Kv7 potassium channels for epilepsy","volume":"39","author":"Perucca","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2026.110970_b0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17512433.2024.2337012","article-title":"A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy","volume":"17","author":"Lattanzi","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2026.110970_b0060","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II . Drugs in more advanced clinical development. Epilepsia 2022;63:2883\u2013910. DOI: 10.1111\/epi.17376.","DOI":"10.1111\/epi.17376"},{"key":"10.1016\/j.yebeh.2026.110970_b0065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamaneurol.2023.3542","article-title":"Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: A Phase 2b randomized clinical trial","volume":"80","author":"French","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/epi4.70015","article-title":"Interim analysis of the long\u2010term efficacy and safety of azetukalner in an ongoing open\u2010label extension study following a phase 2b clinical trial (X\u2010 TOLE) in adults with focal epilepsy","volume":"10","author":"French","year":"2025","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2026.110970_b0075","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Perucca E, Perucca P, Tomson T, et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development. Epilepsia 2024;65:2858\u201382. DOI: 10.1111\/epi.18075.","DOI":"10.1111\/epi.18075"},{"key":"10.1016\/j.yebeh.2026.110970_b0080","doi-asserted-by":"crossref","unstructured":"Le NM, Smith SH, Weberg M, Polega S. Safety, tolerability, and efficacy of bexicaserin in a cohort of participants with developmental and epileptic encephalopathies: Interim results of a Phase 1b\/2a PACIFIC study open-label extension (S20.005) (abstract). Neurology 2025;104 (suppl 1)):2388.","DOI":"10.1212\/WNL.0000000000209114"},{"key":"10.1016\/j.yebeh.2026.110970_b0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/epi.16832","article-title":"The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ?","volume":"62","author":"L\u00f6scher","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nurt.2006.11.016","article-title":"Carisbamate (RWJ-333369)","volume":"4","author":"Novak","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2026.110970_b0095","unstructured":"Praxis Precision Medicines, Inc. Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback (press release, 4 November 2025). https:\/\/investingnews.com\/praxis-announces-accelerated-development-path-for-relutrigine-in-scn2a-and-scn8a-dee-patients-following-positive-fda-feedback\/ (accessed 11 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0100","article-title":"Carisbamate add-on therapy for drug-resistant focal epilepsy","volume":"12(12):CD012121","author":"Lu","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"Supplement 1","key":"10.1016\/j.yebeh.2026.110970_b0105","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.0000000000208551","article-title":"Carisbamate treatment of adult and pediatric patients with Lennox-Gastaut syndrome: a","volume":"104","author":"Vashi","year":"2025","journal-title":"Neurology"},{"issue":"supplement 1","key":"10.1016\/j.yebeh.2026.110970_b0110","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1212\/WNL.0000000000206132","article-title":"Efficacy and safety of ES-481, a novel TARP inhibitor, in drug-resistant epilepsy: A double-blind randomized placebo controlled Phase IIa trial (S19.003)(abstract)","volume":"102","author":"O\u2019Brien","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.110970_b0115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/epi.17149","article-title":"The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers","volume":"63","author":"Kahlig","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0120","unstructured":"Anderson L, Kahlig KM, Souza M, et al. Preclinical findings of relutrigine, a precision sodium channel modulator, point to anticonvulsant potential in Dravet syndrome. 36th International Epilepsy Congress, Lisbon, Portugal, 30 August- 3 September, 2025, Poster P212. https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/08\/P212_Anderson_IEC2025_Dravet.pdf (accessed 11 November 2025."},{"key":"10.1016\/j.yebeh.2026.110970_b0125","unstructured":"Mahalingam R, Oldham M, Patel D, Hard M, Puryear C, Ravina B. A Phase 1 trial evaluating the safety, tolerability, pharmacokinetics and food effect of PRAX-562 in healthy volunteers. 76th Annual Meeting of the American Epilepsy Society (AES), 2-6 December, 2022, Nashville, TN, Abstract 2.24. https:\/\/aesnet.org\/abstractslisting\/a-phase%E2%80%AF1-trial-evaluating-the-safety--tolerability--pharmacokinetics-and-food-effect-of-prax-562-in-healthy-volunteers (accessed 11 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0130","unstructured":"Frizzo S, Spar B, Dalby K, Guest P, Patel D, Jacotin H, et al. Relutrigine demonstrates robust seizure reduction and seizure freedom in DEEs: results from the EMBOLD study. 78th Annual Meeting of the American Epilepsy Society (AES), Los Angeles, CA, 6-10 December 2024, abstract 1.528, https:\/\/aesnet.org\/abstractslisting\/relutrigine-demonstrates-robust-seizure-reduction-and-seizure-freedom-in-dees-results-from-the-embold-study. Full poster available at https:\/\/praxismedicines.com\/wp-content\/uploads\/2024\/12\/Frizzo_AES2024_EMBOLD_Poster_121324.pdf (accessed 12 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0135","unstructured":"Kamireddy S, Frizzo S, Spar B, Guest P, Del Real K, Patel D, et al. Relutrigine demonstrates disease-modifying impact in DEEs: Results from the EMBOLD study. Poster presented at the 79th Annual Meeting of the American Epilepsy Society (AES), Atlanta, GA, 5-9 December 2025. https:\/\/praxismedicines.com\/wp-content\/uploads\/2025\/12\/Gil-Nagel_AES2025_EMBOLD-Topline.pdf (accessed 4 February 2026)."},{"key":"10.1016\/j.yebeh.2026.110970_b0140","unstructured":"Praxis Precision Medicines. Praxis Precision Medicines announces positive results from EMBOLD study for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (press release, 4 December 2025). https:\/\/ir.praxismedicines.com\/news-releases\/news-release-details\/praxis-precision-medicines-announces-positive-results-embold (accessed 4 February 2026)."},{"key":"10.1016\/j.yebeh.2026.110970_b0145","unstructured":"Praxis Precision Medicines. Praxis Precision Medicines announces plans to file an NDA for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies in early 2026. (press release, 11 December 2025). https:\/\/ir.praxismedicines.com\/news-releases\/news-release-details\/praxis-precision-medicines-announces-plans-file-nda-relutrigine (accessed 4 February 2026)."},{"key":"10.1016\/j.yebeh.2026.110970_b0150","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/epi.18287","article-title":"A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat","volume":"66","author":"Kondo","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0155","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1586098","article-title":"Efficacy, safety, and tolerability of soticlestat (TAK-935) as adjunctive therapy in pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome: a meta-analysis of 3 randomized controlled trials","volume":"16","author":"Lanlan","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2026.110970_b0165","doi-asserted-by":"crossref","unstructured":"French J, Bosak M, Kerr WT, Smekens P, Mistry D, Van Der Geyten S, et al. A randomized, double-blind, placebo-controlled, time-to-event study of the efficacy and safety of JNJ-40411813 in combination with levetiracetam or brivaracetam in patients with focal onset seizures. Epilepsia. 2025. DOI: 10.1111\/epi.18707. Online ahead of print.","DOI":"10.1111\/epi.18707"},{"key":"10.1016\/j.yebeh.2026.110970_b0170","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.0000000000012744","article-title":"Monogenic epilepsies: Disease mechanisms, clinical phenotypes, and targeted therapies","volume":"97","author":"Guerrini","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2026.110970_b0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/WCO.0000000000001141","article-title":"The current landscape of epilepsy genetics: where are we, and where are we going?","volume":"36","author":"Ruggiero","year":"2023","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2026.110970_b0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.32033","article-title":"Gene-targeted therapies: overview and implications","volume":"193","author":"Brooks","year":"2023","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.yebeh.2026.110970_b0185","doi-asserted-by":"crossref","unstructured":"Wang S, Perucca E, Berkovic SF, Perucca P. Precision therapies for genetic epilepsies in 2025: Promises and pitfalls. Epilepsia Open. 2025 May 24. Online ahead of print. DOI: 10.1002\/epi4.70065.","DOI":"10.1002\/epi4.70065"},{"key":"10.1016\/j.yebeh.2026.110970_b0190","doi-asserted-by":"crossref","unstructured":"Lauffer MC, van Roon-Mom W, Aartsma-Rus A, N\u2009=\u20091 Collaborative. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun Med (Lond). 2024 ;4(1):6. DOI: 10.1038\/s43856-023-00419-1.","DOI":"10.1038\/s43856-023-00419-1"},{"key":"10.1016\/j.yebeh.2026.110970_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147743","article-title":"Targeted Augmentation of Nuclear Gene output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome","volume":"1775","author":"Wengert","year":"2022","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2026.110970_b0200","unstructured":"Laux L, Sullivan J, Cross JH, Desurkar A, Knupp K, Wheless J, et al. Zorevunersen (STK-001) demonstrates potential for disease modification including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome (DS.) 78th Annual Meeting of the American Epilepsy Society (AES), Los Angeles, CA, December 6-10, 2024, abstract 2.379. https:\/\/aesnet.org\/abstractslisting\/zorevunersen-stk-001-demonstrates-potential-for-disease-modification-including-reductions-in-seizures-and-improvements-in-cognition-and-behavior-in-children-and-adolescents-with-dravet-syndrome-ds#:\u223c:text=Zorevunersen%20(STK%2D001)%20Demonstrates,Adolescents%20with%20Dravet%20Syndrome%20(DS) (accessed 15 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0205","unstructured":"Sullivan J, Perry MS, Brunklaus A, Cross JH, Desrkar A, Laux L, et al. Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and clinically meaningful improvements in cognition and behaviour. 78th Annual Meeting of the American Epilepsy Society (AES), Los Angeles, CA, December 6-10, 2024, abstract 3.364. https:\/\/aesnet.org\/abstractslisting\/patients-with-dravet-syndrome-in-open-label-extension-studies-of-zorevunersen-stk-001-have-durable-reductions-in-seizure-frequency-and-clinically-meaningful-improvements-in-cognition-and-behavior (accessed 15 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0210","unstructured":"Praxis Precision Medicines. Praxis Precision Medicines to present on late-stage programs across epilepsy and movement disorders at the American Academy of Neurology 2025 Annual Meeting. Press release, March 4, 2025. https:\/\/investors.praxismedicines.com\/news-releases\/news-release-details\/praxis-precision-medicines-present-late-stage-programs-across\/ (accessed 15 November 2025)."},{"issue":"7","key":"10.1016\/j.yebeh.2026.110970_b0215","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41591-025-03656-0","article-title":"Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy","volume":"31","author":"Wagner","year":"2025","journal-title":"Nat Med"},{"issue":"S 01","key":"10.1016\/j.yebeh.2026.110970_b0220","first-page":"S1","article-title":"Significant Seizure Reduction in pediatric participants with early-onset SCN2A developmental and epileptic encephalopathy following treatment with elsunersen, a novel antisense oligonucleotide: Findings from the EMBRAVE study","volume":"55","author":"Fazeli","year":"2024","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2026.110970_b0225","unstructured":"Wagner M, Borggraefe I, Wheless J, Troedson C, Howell K, Frizzo S, et al. Clinical updates from the elsunersen emergency use program: A novel ASO for treatment of early onset SCN2A developmental and epileptic encephalopathy. 78th Annual Meeting of the American Epilepsy Society (AES), Los Angeles, CA, December 6-10, 2024, abstract 1.526. https:\/\/aesnet.org\/abstractslisting\/clinical-updates-from-the-elsunersen-emergency-use-program-a-novel-aso-for-treatment-of-early-onset-scn2a-developmental-and-epileptic-encephalopathy (accessed 15 November 2025)."},{"issue":"6","key":"10.1016\/j.yebeh.2026.110970_b0230","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s13311-023-01434-9","article-title":"Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a Lafora disease mouse model","volume":"20","author":"Donohue","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2026.110970_b0235","unstructured":"Kelly K. Safety study update - February 2025. Posted February 20, 2025. https:\/\/chelseashope.org\/safety-study-update\/ (accessed 15 November 2025)."},{"issue":"2","key":"10.1016\/j.yebeh.2026.110970_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/a-2399-0191","article-title":"Precision medicine in Angelman syndrome","volume":"56","author":"Manssen","year":"2025","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2026.110970_b0245","unstructured":"Ionis Pharmaceuticals. First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome, Press release, June 11, 2025. https:\/\/ir.ionis.com\/news-releases\/news-release-details\/first-patient-dosed-pivotal-phase-3-reveal-clinical-study-ion582\/ (accessed 15 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0250","unstructured":"Ultragenyx Pharmaceutical. Ultragenyx presents positive update on GTX-102 Angelman syndrome program at FAST\u2019s 17th Annual Global Science Summit. Press release, November 9, 2024. https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-presents-positive-update-gtx-102-angelman-syndrome (accessed 15 November 2025)."},{"issue":"2","key":"10.1016\/j.yebeh.2026.110970_b0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/WCO.0000000000001349","article-title":"State-of-the-art gene therapy in epilepsy","volume":"38","author":"Walker","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0260","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, Perucca E, Perucca P, Tomson T, et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia. 2024;65(10):2831-2857. DOI: 10.1111\/epi.18056.","DOI":"10.1111\/epi.18056"},{"key":"10.1016\/j.yebeh.2026.110970_b0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/hum.2022.037","article-title":"Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates","volume":"33","author":"Tanenhaus","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.yebeh.2026.110970_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101342","article-title":"A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsy","volume":"32","author":"Baudouin","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.yebeh.2026.110970_b0275","unstructured":"Capsida Biotherapeutics. Capsida receives FDA IND clearance for its first-in-class, IV-administered gene therapy for STXBP1 developmental and epileptic encephalopathy. Press release, May 12, 2025. https:\/\/capsida.com\/capsida-receives-fda-ind-clearance-for-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-developmental-and-epileptic-encephalopathy\/ (accessed 15 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2023.08.013","article-title":"Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy","volume":"30","author":"Bershteyn","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"suppl 1","key":"10.1016\/j.yebeh.2026.110970_b0285","article-title":"First-in-human trial of NRTX-1001 GABAergic interneuron cell therapy for focal epilepsy - Updated clinical trial results","volume":"104","author":"Hixson","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.110970_b0290","unstructured":"Neurona Therapeutics. Neurona Therapeutics presents new long-term clinical data from NRTX-1001 cell therapy trials at 2025 Annual Meeting of the American Epilepsy Society. Press release, December 8, 2025 https:\/\/www.neuronatherapeutics.com\/news\/press-releases\/120825\/ (accessed 7 February 2026)."},{"key":"10.1016\/j.yebeh.2026.110970_b0295","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.54.7.1529","article-title":"Reduction of human visual cortex excitability using 1-Hz transcranial magnetic stimulation","volume":"54","author":"Boroojerdi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.110970_b0300","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1212\/WNL.48.5.1398","article-title":"Depression of motor cortex excitability by low\u2010frequency transcranial magnetic stimulation","volume":"48","author":"Chen","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.110970_b0305","doi-asserted-by":"crossref","unstructured":"Walton D, Spencer DC, Nevitt SJ, Michael BD. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database of Systematic Reviews 2021;4(4):CD011025. DOI: 10.1002\/14651858.CD011025.pub3.","DOI":"10.1002\/14651858.CD011025.pub3"},{"key":"10.1016\/j.yebeh.2026.110970_b0310","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.20950","article-title":"A randomized clinical trial of repetitive transcranial magnetic stimulation in patients with refractory epilep-sy","volume":"60","author":"Fregni","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.seizure.2025.06.020","article-title":"Efficacy of repetitive transcranial magnetic stimulation (rTMS) therapy in children with drug refractory focal epilepsy \u2013 a randomized trial","volume":"130","author":"Sinha","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.110970_b0320","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.seizure.2025.07.015","article-title":"Repetitive transcranial magnetic stimulation for the treatment of focal drug-resistant epilepsy: a crossover, randomized, single-blinded, sham-controlled clinical trial","volume":"131","author":"Melus","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.110970_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1462364","article-title":"Transcranial direct current stimulation in the management of epilepsy: a meta-analysis and systematic review","volume":"15","author":"Chen","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2025.103142","article-title":"The safety and effectiveness of tDCS for epileptic patients: a systematic review and meta-analysis","volume":"89","author":"Ding","year":"2025","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.yebeh.2026.110970_b0335","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10072-024-07866-1","article-title":"Efficacy and safety of transcranial direct current stimulation (tDCS) in treatment of refractory epilepsy: an updated systematic review and meta-analysis of randomized sham-controlled trials","volume":"46","author":"Hawas","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2026.110970_b0340","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000543106","article-title":"Effectiveness of transcranial direct current stimulation in treating drug-resistant focal epilepsy: a systematic review and meta-analysis","volume":"88","author":"Marin-Casta\u00f1eda","year":"2025","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.909421","article-title":"Transcranial current stimulation in epilepsy: a systematic review of the fundamental and clinical aspects","volume":"16","author":"Simula","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.yebeh.2026.110970_b0350","doi-asserted-by":"crossref","unstructured":"Sudbrack-Oliveira P, Barbosa MZ, Thome-Souza S, Razza LB, Gallucci-Neto J, Da Costa Lane Valiengo L, et al. Transcranial direct current stimulation (tDCS) in the management of epilepsy: A systematic review. Seizure 2021;86:85\u201395. DOI: 10.1016\/j.seizure.2021.01.020.","DOI":"10.1016\/j.seizure.2021.01.020"},{"key":"10.1016\/j.yebeh.2026.110970_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107456","article-title":"Evaluating the efficacy of transcranial direct current stimulation for refractory epilepsy: a meta-analysis of RCTs and non-RCTs","volume":"208","author":"Sun","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2026.110970_b0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brs.2019.09.006","article-title":"Transcranial direct current stimulation reduces seizure frequency in patients with refractory focal epilepsy: a randomized, double-blind, sham-controlled, and three-arm parallel multicenter study","volume":"13","author":"Yang","year":"2020","journal-title":"Brain Stimul"},{"key":"10.1016\/j.yebeh.2026.110970_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108876","article-title":"Repeated long sessions of transcranial direct current stimulation reduces seizure frequency in patients with refractory focal epilepsy: an open-label extension study","volume":"135","author":"Yang","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.110970_b0370","doi-asserted-by":"crossref","unstructured":"El-Nakah O, AbdelKader AA, Kishk NA, Azmy RM, Al Menabbawy MK, Mourad HH, et al. The impact of transcranial direct current stimulation on drug-resistant temporal lobe epilepsy. J Clin Neurophysiol 2025. Online ahead of print DOI: 10.1097\/WNP.0000000000001201.","DOI":"10.1097\/WNP.0000000000001201"},{"key":"10.1016\/j.yebeh.2026.110970_b0375","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/WNP.0000000000000838","article-title":"Personalized, multisession, multichannel transcranial direct current stimulation in medication-refractory focal epilepsy: an open-label study","volume":"40","author":"Kaye","year":"2023","journal-title":"J Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2026.110970_b0380","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaf012","article-title":"Epileptogenic zone characteristics determine effectiveness of electrical transcranial stimulation in epilepsy treatment","volume":"7","author":"Daoud","year":"2024","journal-title":"Brain Commun"},{"key":"10.1016\/j.yebeh.2026.110970_b0385","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/epi4.70055","article-title":"Personalized multichannel transcranial direct current electrical stimulation (tDCS) in drug\u2010resistant epilepsy: a SEEG based open\u2010labeled study","volume":"10","author":"Bartolomei","year":"2025","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2026.110970_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2025.110390","article-title":"Epicranial focal cortex stimulation for minimally invasive neuromodulation of the epileptogenic region: a review","volume":"168","author":"Schulze-Bonhage","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.110970_b0395","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/jamaneurol.2023.0066","article-title":"Focal cortex stimulation with a novel implantable device and antiseizure outcomes in 2 prospective multicenter single-arm trials","volume":"80","author":"Schulze-Bonhage","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0400","doi-asserted-by":"crossref","unstructured":"Alhourani A, Chao L-Y, Chang EF, Rao VR. Systematic review and meta-analysis of bilateral centromedian nucleus neuromodulation for multifocal and generalized epilepsy. Neuromodulation 2025:S1094715925001527. DOI: 10.1016\/j.neurom.2025.04.008.","DOI":"10.1016\/j.neurom.2025.04.008"},{"key":"10.1016\/j.yebeh.2026.110970_b0405","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.26280","article-title":"DBS of thalamic centromedian nucleus for Lennox\u2013Gastaut syndrome (ESTEL Trial)","volume":"91","author":"Dalic","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2026.110970_b0410","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/epi.16657","article-title":"Cortex leads the thalamic centromedian nucleus in generalized epileptic discharges in Lennox\u2010Gastaut syndrome","volume":"61","author":"Dalic","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0415","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1528-1167.2006.00593.x","article-title":"Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome","volume":"47","author":"Velasco","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0420","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3171\/2024.2.PEDS23531","article-title":"Responsive neu-rostimulation of thalamic nuclei for regional and multifocal drug-resistant epilepsy in children and young adults","volume":"34","author":"Mohanty","year":"2024","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.yebeh.2026.110970_b0425","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/epi4.70069","article-title":"Chronic thalamic recordings for idiopathic generalized epilepsy and Lennox\u2013Gastaut syndrome: Ictal and interictal electrophysiological findings","volume":"10","author":"Bullinger","year":"2025","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2026.110970_b0430","unstructured":"Medical Device Network. NeuroPace reports initial one-year outcomes from trial of RNS system. 22 May 2025. https:\/\/www.medicaldevice-network.com\/news\/neuropace-outcomes-trial\/ (accessed 15 November 2025)."},{"key":"10.1016\/j.yebeh.2026.110970_b0435","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eplepsyres.2019.01.003","article-title":"Electrical cortical stimulation for refractory focal epilepsy: a long-term follow-up study","volume":"151","author":"Chang","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2026.110970_b0440","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/epi.12525","article-title":"Chronic subthreshold subdural cortical stimulation for the treatment of focal epilepsy originating from eloquent cortex","volume":"55","author":"Child","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106392","article-title":"Subacute neocortical stimulation (SNCS) and its effects on epileptic activity in adults and children diagnosed with focal cortical dysplasia (FCD)","volume":"166","author":"Freigang","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2026.110970_b0450","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcz010","article-title":"Chronic subthreshold cortical stimulation and stimulation-related EEG biomarkers for focal epilepsy","volume":"1","author":"Lundstrom","year":"2019","journal-title":"Brain Commun"},{"key":"10.1016\/j.yebeh.2026.110970_b0455","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.seizure.2013.08.005","article-title":"Seizure outcome after hippocampal deep brain stimulation in a prospective cohort of patients with refractory temporal lobe epilepsy","volume":"23","author":"Cukiert","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.110970_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2016.01.018","article-title":"Hippocampal deep brain stimulation in nonlesional refractory mesial temporal lobe epilepsy","volume":"37","author":"Jin","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.110970_b0465","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1528-1157.2000.tb00135.x","article-title":"Subacute electrical stimulation of the hippocampus blocks intractable temporal lobe seizures and paroxysmal EEG activities","volume":"41","author":"Velasco","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0470","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/epi.17722","article-title":"Initial case series of a novel sensing deep brain stimulation device in drug\u2010resistant epilepsy and consistent identification of alpha\/beta oscillatory activity: a feasibility study","volume":"64","author":"Chua","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0475","first-page":"1","article-title":"An embedded intracranial seizure monitor for objective outcome measurements and rhythm identification","author":"Fleming","year":"2023","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"issue":"11","key":"10.1016\/j.yebeh.2026.110970_b0480","first-page":"786","article-title":"Modest growth seen in the epilepsy market","volume":"39","author":"Gohil","year":"2014","journal-title":"Pharmacy & Therapeutics"},{"issue":"8","key":"10.1016\/j.yebeh.2026.110970_b0485","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.3390\/ijms25084161","article-title":"Neuroinflammation and epilepsy: from pathophysiology to therapies based on repurposing drugs","volume":"25","author":"Sanz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.yebeh.2026.110970_b0490","unstructured":"Ray A, Koh, S, Donner E, Aungaroon G, Jeong A, Mathews, M. et al. EPX-100 as adjunctive therapy in patients with Dravet syndrome: Preliminary results from the open-label extension phase of the ARGUS study. 79th Annual Meeting of the American Epilepsy Society (AES), Atlanta, GA, December 5-9, 2025, abstract 3.353. https:\/\/aesnet.org\/abstractslisting\/epx-100-as-adjunctive-therapy-in-patients-with-dravet-syndrome-preliminary-results-from-the-open-label-extension-phase-of-the-argus-study (accessed 16 February 2026)."},{"key":"10.1016\/j.yebeh.2026.110970_b0495","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/epi.17441","article-title":"A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato alprazolam for rapid seizure termination","volume":"64","author":"French","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.110970_b0500","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075888","article-title":"Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol","volume":"13","author":"Vivash","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2026.110970_b0505","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/epi4.12656","article-title":"Efficacy and safety of adjunctive padsevonil in adults with drug-resistant focal epilepsy: results from two double-blind, randomized, placebo-controlled trials","volume":"7","author":"Rademacher","year":"2022","journal-title":"Epilepsia Open"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026000910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026000910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:34:30Z","timestamp":1776699270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026000910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":101,"alternative-id":["S1525505026000910"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.110970","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel epilepsy treatments in clinical development","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.110970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110970"}}